Globally, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus has variably affected the various parts of the world and has been a major cause for significant morbidity and mortality. Coronavirus disease 2019 (COVID‐19), the disease caused by SARS‐CoV‐2, has been reported to have multiple clinical manifestations, although primarily they have been pulmonary manifestations. Hepatic manifestations have variably been present in up to 50% of infected individuals. 1 ,  2  The spectrum ranges from asymptomatic abnormalities in hepatic biochemical tests to the rare case of acute liver failure. The cause for hepatic manifestations is unclear at this stage and may be caused by a variety of reasons, such as a manifestation of a systemic illness, ischemic liver injury, immune‐mediated liver injury, drug‐induced liver injury, or a direct cytopathic effect of the virus. 3 ,  4 ,  5 ,  6  Not uncommonly, patients have concomitant infections, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infection, either alone or as co‐infections, and the impact of the pandemic and SARS‐CoV‐2 on these infections and associated liver diseases is unknown. Further, the implications in people who inject drugs (PWIDs) may be unique. Observations continue to evolve regarding hepatic manifestations and challenges with COVID‐19 and the liver, and as such, expectations and guidance on issues relevant to the multiple viral infections are important.